A place to orient
Useful context before strong conclusions
Cautera helps people understand the evolving evidence, safety concerns, and regulatory status surrounding ibogaine and related compounds. It presents uncertainty plainly and supports informed conversations without promoting treatment. For a broader starting point on whether ibogaine treatment works, the central question is not just whether change is reported, but how the evidence was gathered, for whom, and with what follow-up.
Our approach is explained in the principles behind Cautera: independence, evidence before claims, safety clarity, plain language, and respect for uncertainty. The resource is for people affected by substance use, families, and others seeking clear context rather than a clinical recommendation.
“A promising claim and a reliable answer are not the same thing.”
Featured guide
A framework for weighing “does it work?”
Evidence is easier to interpret when questions about outcomes, study design, risks, setting, and longer-term follow-up are kept visible together. Cautera organizes those questions without implying that an information page can determine what is right for any individual.
Information services
Ways to navigate the topic
These materials are designed for careful reading, comparison, and discussion. They do not replace medical, legal, or emergency guidance.
01 · Evidence guides
Research summaries
Plain-language summaries distinguish early findings, observational reports, and unanswered questions. The evidence review is structured to make the limits of existing research as visible as reported outcomes.
02 · Decision framework
Claims in context
Compare what a claim says with what would be needed to support it: population, comparison group, safety monitoring, time horizon, and independent replication. For a focused discussion of addiction-related claims, see ibogaine treatment and drug addiction.
03 · Safety reference
Risk questions
Safety information is not an afterthought. Ibogaine has been associated with serious cardiac concerns, and the safety and risks guide keeps those concerns alongside uncertainty about benefits.
04 · Comparison support
Separate sources from conclusions
Comparisons help readers identify when a website is describing research, making a marketing claim, or leaving important details out. Context matters when evaluating material from an ibogaine clinic in Tijuana or any other treatment-facing source.
Regulatory status belongs in the conversation.
In the United States, ibogaine is listed as a Schedule I controlled substance under the Drug Enforcement Administration’s controlled-substances listing. That status does not answer every research question, but it does affect what can be offered, studied, and claimed in different settings.